↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Overview of attention for article published in Neuropsychiatric Disease and Treatment, February 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
54 Mendeley
Title
<p>Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population</p>
Published in
Neuropsychiatric Disease and Treatment, February 2019
DOI 10.2147/ndt.s189668
Authors

Adam J Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, David Hough, Ludger Hargarter

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 54 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 30%
Researcher 7 13%
Student > Master 6 11%
Student > Ph. D. Student 3 6%
Other 3 6%
Other 6 11%
Unknown 13 24%
Readers by discipline Count As %
Medicine and Dentistry 15 28%
Psychology 6 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Nursing and Health Professions 3 6%
Biochemistry, Genetics and Molecular Biology 3 6%
Other 7 13%
Unknown 15 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2019.
All research outputs
#7,505,392
of 14,537,474 outputs
Outputs from Neuropsychiatric Disease and Treatment
#913
of 2,487 outputs
Outputs of similar age
#115,022
of 264,497 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#4
of 5 outputs
Altmetric has tracked 14,537,474 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,487 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,497 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.